Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urodynamic Effects of Tadalafil in BPH
NCT00386009Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Placebo with Tadalafil (2 arms). Primary endpoint: Detrusor Pressure at Peak Urinary Flow Rate at 12 weeks. Started Oct 2006; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00386009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386009.